OncoTherapeutica, Inc. — Department of Health and Human Services SBIR Phase I: NCI

Description

Prostate cancer PC is the most frequently diagnosed malignancy in men and the second leading cause of cancer death In this Phase I SBIR proposal we will develop a novel radioIodinated I ProDrug IPD that has been designed to be specifically hydrolyzed within primary and metastatic well differentiated and poorly differentiated PC lesion into radioiodinated Drugs ID that are trapped within these tumors SPECIFIC AIMS Synthesize and characterize IPD IPD derivative and corresponding IDs IDs inject IPD into PC bearing mice determine tumor uptake and tumor to normal tissue ratios over time and estimate the doses deposited in the tumor and normal tissues and synthesize IPD derivative identify its MTD in mice and confirm therapeutic efficacy in PC bearing mice We anticipate that these studies will identify a novel and commercially viable IPD that will deposit therapeutically effective i e curative radiation doses specifically within PC lesions and that this radiopharmaceutical post future Phase II SBIR funding and VC funded clinical trials will i enable the coupling of imaging IPD and treatment IPD and therefore the personalization of treatment ii move meaningful intervention to an earlier point and forestall the development of metastatic disease and iii diminish eliminate the death of patients with this devastating disease